Page 8 - Cell Line News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Watch the latest scientific webinars on SelectScience.

The study explores the efficacy of three-dose monovalent or bivalent vaccinations in neutralizing newly emerged SARS-CoV-2 variants BA.2.86 and FLip. While BA.2.86 showed lower immune evasion abilities compared to recent XBB variants, it was less effectively neutralized by the monoclonal antibody S309, raising questions about vaccine efficacy against evolving strains.

In this interview, News-Medical had the opportunity to speak with Dr. Xiaobing Han, Principal Scientist for Antibody Discovery at Rapid Novor.

Equipping cancer-infecting, or oncolytic, viruses with tumor-inhibiting genetic cargo stimulates the immune system and helps immunotherapy to shrink or completely clear aggressive tumors in mice, according to a new study in the Journal of Experimental Medicine led by University of Pittsburgh and UPMC researchers.

BALTIMORE — The family of Henrietta Lacks filed a lawsuit Thursday against a California-based pharmaceutical company in a continuation of her descendants’ efforts to recoup profits from companies they say are making money off the HeLa cell line. The new lawsuit, against Ultragenyx Pharmaceutical, a publicly traded company specializing in treatments for rare diseases, comes just over a week ...